Table 1.
Characteristics of the patients harboring HER2 alteration
| Characteristic | HER2 altered (n=36) | Exon20 insertion (n=22) | HER2 amplification (n=15) | p-value |
|---|---|---|---|---|
| Age at diagnosis (yr) | 58 | 60.2 | 56.4 | |
| Sex | 0.093 | |||
| Men | 20 (55.6) | 10 (45.5) | 11 (73.3) | |
| Women | 16 (44.4) | 12 (54.5) | 4 (26.7) | |
| ECOG PS | 0.819 | |||
| 0 | 4 (11.1) | 3 (13.6) | 1 (6.7) | |
| 1 | 30 (83.3) | 18 (81.8) | 13 (86.7) | |
| 2 | 2 (5.6) | 1 (4.5) | 1 (6.7) | |
| Tobacco | 0.084 | |||
| Never | 18 (50.0) | 14 (63.6) | 4 (26.7) | |
| Former | 11 (30.6) | 5 (22.7) | 6 (40.0) | |
| Current | 7 (19.4) | 3 (13.6) | 5 (33.3) | |
| Stage at diagnosis | 0.753 | |||
| I | 5 (13.9) | 2 (9.1) | 3 (20.0) | |
| II | 3 (8.3) | 2 (9.1) | 1 (6.7) | |
| III | 4 (11.1) | 2 (9.1) | 2 (13.3) | |
| IV | 24 (66.7) | 16 (72.7) | 9 (60.0) | |
| Metastasis sites | ||||
| Bone | 21 (58.3) | 14 (63.6) | 8 (53.3) | 0.531 |
| Pleura | 18 (50.0) | 12 (54.5) | 6 (40.0) | 0.385 |
| Brain | 13 (36.1) | 8 (36.4) | 5 (33.3) | 0.850 |
| Contralateral metastasis | 11 (30.6) | 6 (27.3) | 5 (33.3) | 0.728 |
| Liver | 7 (19.4) | 7 (31.8) | 0 | 0.028 |
| Distant LN | 7 (19.4) | 4 (18.2) | 3 (20.0) | 0.808 |
| Adrenal | 4 (11.1) | 4 (18.2) | 0 | 0.131 |
| LMS | 3 (8.3) | 2 (9.1) | 1 (6.7) | 1.000 |
| Thyroid | 1 (2.8) | 1 (4.5) | 0 | 1.000 |
| Histology | 0.021 | |||
| ADC | 32 (88.9) | 22 (100) | 11 (73.3) | |
| SQC | 4 (11.1) | 0 | 4 (26.7) | |
| EGFR(+) | 0.002 | |||
| Wild type | 30 (83.3) | 22 (100) | 9 (60.0) | |
| Mutation | 6 (16.7) | 0 | 6 (40.0) | |
| ALK(+) | 0.505 | |||
| Wild type | 34 (94.4) | 20 (90.9) | 15 (100) | |
| Mutation | 2 (5.6) | 2 (9.1) | 0 |
Values are presented as number (%). HER2, human epidermal growth factor receptor 2; ECOG PS, Eastern Cooperative Oncology Group performance status; LN, lymph node; LMS, leptomeningeal seeding; ADC, adenocarcinoma; SQC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.